Objectives: To investigate the clinical efficacy and safety of a newly developed diclofenac patch in the topical treatment of blunt impact injuries.
Methods: This was a randomised, placebo controlled, double blind, multicentre study in 120 patients with traumatic blunt soft tissue injury. Within 3 h of the injury participants of sport competitions and training camps were enrolled and treated twice daily with the diclofenac or a placebo patch over a period of 7 days. Patients were randomised (1:1) to two parallel groups. Tenderness produced by pressure was measured twice daily during the first 3 days after enrollment as well as at day 7. Tenderness was defined as the amount of pressure (measured by a calibrated caliper at the centre of the injury) that first produced a pain reaction as reported by the patient.
Results: The primary efficacy variable was the area under the curve for tenderness over the first 3 days. The diclofenac patch was significantly more effective than placebo (p<0.0001). The treatment effect was 64.7 kp h/cm2 (95% confidence interval 48.7 to 80.9) between diclofenac and placebo patches. These results were supported by all secondary efficacy variables. The diclofenac patch produced rapid pain relief as reflected by the time to reach resolution of pain at the injured site which was significantly shorter compared to placebo (p<0.0001). The diclofenac patch was well tolerated. The most frequently observed adverse events were local cutaneous adverse reactions (pruritus, rash) of minor severity occurring with the same frequency as in the placebo group.
Conclusions: A newly developed diclofenac patch is effective and safe for the treatment of blunt impact injuries.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1724805 | PMC |
http://dx.doi.org/10.1136/bjsm.2003.005017 | DOI Listing |
J Gastroenterol Hepatol
December 2024
Hisamitsu Pharmaceutical Co., Inc., Tokyo, Japan.
Int J Biol Macromol
December 2024
Cellulose & Composites Research Group, Department of Materials Science and Metallurgical Engineering, Indian Institute of Technology, Hyderabad, Kandi, 502285 Sangareddy, Telangana, India. Electronic address:
Bacterial cellulose (BC) stands out as a promising candidate for novel drug delivery systems due to its micro-mesoporous nanofibrous interconnected structure. However, its performance is limited by the burst release of hydrophilic drugs and lower incorporation of the less water-soluble or insoluble drugs. In this study, we explored its potential as a drug carrier for two distinct types of drugs: Diclofenac sodium and Simvastatin, representing water-soluble and water insoluble compounds, respectively.
View Article and Find Full Text PDFSports Health
October 2024
Department of Community Health and Family Medicine, University of Florida, Gainesville, Florida.
Context: In patients with musculoskeletal (MSK) conditions, pain is the leading contributor to disability and significantly limits mobility and dexterity. This narrative review describes the efficacy and safety of topical analgesics in common use today.
Evidence Acquisition: Secondary literature gained via a literature search using PubMed.
J Back Musculoskelet Rehabil
November 2024
Affiliated Hospital of Northwest University for Nationalities, Lanzhou, China.
Background: In China, Tongluo-Qutong rubber plaster (TQRP) is commonly used for cervical spondylotic radiculopathy, but lacks high-quality trials.
Objective: This study aimed to conduct a multicenter, open-label, parallel-group, randomized controlled trial in China to investigate the practical efficacy and safety of TQRP in the treatment of CSR.
Methods: A total of 240 patients diagnosed with CSR were recruited for the investigation from multiple hospitals in Gansu province, China.
Contact Dermatitis
November 2024
Department of Occupational and Environmental Dermatology, Skåne University Hospital, Lund University, Malmö, Sweden.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!